Unlocking the promise of innate biology through the HLA-G/ILT2/ILT4 pathway

<p>Inhibitory immune pathways have gained considerable attention following the clinical success of immune checkpoint inhibitors in cancer. While much focus has been placed on classical checkpoints such as programmed cell death protein-1 (PD-1)/programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4), alternative immunosuppressive mechanisms are increasingly recognized as contributors to immune evasion, tumor progression, and therapeutic resistance. Among…